Vaccinex reports positive SIGNAL-AD Phase 1b/2 data for pepinemab in Alzheimer's

VACCINEX, INC.

Primary safety endpoint met: pepinemab well-tolerated; no serious treatment-related adverse events.
Secondary endpoint: statistically significant increase in FDG-PET signal in medial temporal cortex (p=0.0297) in MCI patients over 12 months.
Results echo prior Phase 2 Huntington's data, suggesting similar mechanism targeting astrocyte activation.
Company actively pursuing a pharmaceutical partner for late-stage development in Alzheimer's disease.
Pepinemab has been well-tolerated in over 600 patients across AD, HD, and MS trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.